Plain-English translation of NCT07381829 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called combined with different standard chemotherapy drugs to treat advanced lung cancer. Researchers want to find the safest and most effective dose of to use with chemotherapy, and to see how well this combination works for patients whose cancer has spread or cannot be surgically removed. The medication is given as an IV infusion once every three weeks.
Advanced lung cancer is difficult to treat, and current therapies don't work well enough for all patients. This medication is designed to boost the immune system's ability to fight cancer, and researchers believe combining it with chemotherapy may help more patients respond to treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive intravenously (through an IV) once every three weeks, combined with one of several standard chemotherapy regimens depending on which group you are assigned to. You would visit the clinic regularly for treatment infusions, blood tests, and imaging scans to monitor how well the treatment is working and to check for side effects. The study follows different dosing schedules to find the safest dose, and involves approximately 328 participants across multiple cancer centers.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China